Hoopoe
Senior Member (Voting Rights)
Identifying subtypes of ME/CFS has the potential to greatly accelerate research, however definitions of subtypes of ME/CFs only make sense if they reflect a true underlying biological difference.
It occurred to me that subtyping by age of onset could be reliable method for selecting a more homogeneous group of patients. In ME/CFS we seem to have two distinct peaks in the age of onset: one around 15, another around 35-40 (in women). These two peaks must reflect, at least in part, two different biological vulnerabilities that emerge during development and aging, two different paths that led to a ME/CFS-like illness.
Selecting patients with similar age of onset is presumably a way of selecting patients with similar age-related biological vulnerabilities. It doesn't depend on knowing what these factors are.
It occurred to me that subtyping by age of onset could be reliable method for selecting a more homogeneous group of patients. In ME/CFS we seem to have two distinct peaks in the age of onset: one around 15, another around 35-40 (in women). These two peaks must reflect, at least in part, two different biological vulnerabilities that emerge during development and aging, two different paths that led to a ME/CFS-like illness.
Selecting patients with similar age of onset is presumably a way of selecting patients with similar age-related biological vulnerabilities. It doesn't depend on knowing what these factors are.
Last edited:
